Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.64 |
| ▸ | NPC1 | O15118 | 8/20 | 0.64 |
| ▸ | TP53 | P04637 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | GRM5 | P41594 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | CASP3 | P42574 | 2/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13415304 | 0.90 | TP53 (0.64) | RAB9ANPC1TP53MAPTGRM5 | |
| SCHEMBL138239 | 0.84 | NPC1 (0.59) | RAB9ANPC1TP53MAPTGRM5 | |
| SCHEMBL16579451 | 0.84 | TP53 (0.70) | RAB9ANPC1TP53MAPTSMN1; SMN2 | |
| SCHEMBL2618900 | 0.84 | TP53 (0.70) | RAB9ANPC1TP53MAPTGRM5 | |
| SCHEMBL13882259 | 0.84 | RAB9A (0.77) | RAB9ANPC1TP53MAPTGRM5 | |
| SCHEMBL13167092 | 0.84 | TP53 (0.70) | RAB9ANPC1TP53MAPTSMN1; SMN2 | |
| SCHEMBL10094737 | 0.82 | TP53 (0.60) | RAB9ANPC1TP53MAPTGRM5 | |
| SCHEMBL2619077 | 0.82 | TP53 (0.68) | RAB9ANPC1TP53MAPTSMN1; SMN2 | |
| SCHEMBL860042 | 0.82 | TP53 (0.56) | RAB9ANPC1TP53MAPTGRM5 | |
| SCHEMBL13114296 | 0.82 | MAPT (0.83) | RAB9ANPC1TP53MAPTGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732078-B2 | Therapeutic use of imidazopyridine derivatives | SANOFI (FR) | 2017-08-15 | — | — | US | disclosed |
| US-9452164-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2016-09-27 | — | — | US | disclosed |
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| EP-2800566-B1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI SA (FR) | 2015-10-28 | — | — | EP | disclosed |
| EP-2590976-B1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2015-09-16 | — | — | EP | disclosed |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-08-28 | — | — | US | disclosed |
| US-8759344-B2 | Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-06-24 | — | — | US | disclosed |
| WO-2013102860-A1 | THERAPEUTIC USE OF IMIDAZOPYRIDINE DERIVATIVES | SANOFI (FR) | 2013-07-11 | — | — | WO | disclosed |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-09 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20090233009-A1 | COMPOUND, COMPOSITION, RETARDATION PLATE, ELLIPTICALLY-POLARIZING PLATE AND LIQUID-CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090096961-A1 | OPTICAL FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2009-04-16 | — | — | US | disclosed |
| US-20090091690-A1 | Optical Compensation Film, Polarizing Plate and Liquid Crystal Display Device | FUJIFILM CORPORATION (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090068378-A1 | DISCOTIC NEMATIC MATERIAL, COMPOSITION, RETARDATION PLATE, ELLIPTICALLY-POLARIZING PLATE AND COMPOUND | FUJIFILM CORPORATION (JP) | 2009-03-12 | — | — | US | disclosed |
| US-7431972-B2 | Optical film, and polarizing plate and liquid crystal display device using the same | FUJIFILM CORPORATION (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20070259874-A1 | Phosphodiesterase Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2007-11-08 | — | — | US | disclosed |
| US-20070259874-A1 | Phosphodiesterase Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2007-11-08 | — | — | US | disclosed |
| US-20070065601-A1 | Optical film, and polarizing plate and liquid crystal display device using the same | FUJI PHOTO FILM CO., LTD. (JP) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068378-A1 | DISCOTIC NEMATIC MATERIAL, COMPOSITION, RETARDATION PLATE, ELLIPTICALLY-POLARIZING PLATE AND COMPOUND | H1-2, H1-0, CCNL2 | RAB9A 1669/4885NPC1 1265/4885TP53 3006/4885 |
| US-20140243328-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | RAB9A 1969/4885NPC1 2974/4885TP53 1684/4885 |
| US-20140343054-A1 | Therapeutic Use of Imidazopyridine Derivatives | CCNY, UTS2R, WNK2 | RAB9A 2031/4885NPC1 4542/4885TP53 158/4885 |
| US-20130116250-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CCNY, ENY2, PAH | RAB9A 1969/4885NPC1 2974/4885TP53 1684/4885 |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | RAB9A 2645/4885NPC1 1132/4885TP53 4710/4885 |
| US-20090233009-A1 | COMPOUND, COMPOSITION, RETARDATION PLATE, ELLIPTICALLY-POLARIZING PLATE AND LIQUID-CRYSTAL DISPLAY DEVICE | PYM1, CCNA1, CCND1 | RAB9A 2026/4885NPC1 4680/4885TP53 1654/4885 |
| US-20070259874-A1 | Phosphodiesterase Inhibitors | PDE4A, PDE3B, PDE7A | RAB9A 301/4885NPC1 3945/4885TP53 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.